Evidence map›Paper›PMID 21292307›Full record

ArticleHuman pathology2011

Subcellular localization of p27 and prostate cancer recurrence: automated digital microscopy analysis of tissue microarrays.

Viju Ananthanarayanan, Ryan J Deaton, Anup Amatya, Virgilia Macias, Ed Luther, Andre Kajdacsy-Balla, Peter H Gann

Abstract readComparative Study
In one paragraph

Article in Human pathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Subclonal Complete Loss of CDKN1B as a Common Genomic Alteration in Prostate Cancer: Associations With Race and Prostate Cancer Outcomes.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2026
    Article
  2. Article
  3. Article
  4. Arylsulfatase B is reduced in prostate cancer recurrences.Cancer biomarkers : section A of Disease markers · 2017
    Article
  5. Review
  6. Association of cytoplasmic p27 expression with an unfavorable response to cisplatin-based chemotherapy and poor outcomes in non-small cell lung cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Viju AnanthanarayananDepartment of Pathology, University of Illinois at Chicago, Chicago, IL 60612, USA.
Ryan J Deaton
Anup Amatya
Virgilia Macias
Ed Luther
Andre Kajdacsy-Balla
Peter H Gann
University of Illinois Chicago · US

Funding

NYU COOPERATIVE PROSTATE CANCER TISSUE RESOURCEU01CA086772 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MELAMED, JONATHAN · 2000 to 2005
$2.4M
Validation of Digital Morphometry for Cancer Risk in Benign Prostate BiopsiesR01CA155301 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI GANN, PETER H. · 2011 to 2015
$1.7M
Effects of Lycopene on High-Risk Prostatic TissueR01CA090759 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI GANN, PETER H. · 2002 to 2005
$1.4M
NCI NIH HHS R01 CA090759NCI NIH HHS R01 CA155301NCI NIH HHS R01-CA90759NCI NIH HHS U01 CA086772NCI NIH HHS U01-CA86772
6 · The paper itself

Abstract

Previous investigations have linked decreased nuclear expression of the cell cycle inhibitor p27 with poor outcome in prostate cancer. However, these reports are inconsistent regarding the magnitude of that association and its independence from other predictors. Moreover, cytoplasmic translocation of p27 has been proposed as a negative prognostic sign. Given the cost and accuracy limitations of manual scoring, particularly of tissue microarrays, we determined if laser-based fluorescence microscopy could provide automated analysis of p27 in both nuclear and cytoplasmic locations and, thus, clarify its significance as a prognostic biomarker. We constructed tissue microarrays covering 202 recurrent cases (rising prostate-specific antigen) and 202 matched controls without recurrence. Quadruplicate tumor samples encompassed 5 slides and 1616 cancer histospots. Cases and controls matched on age, Gleason grade, stage, and hospital. We immunolabeled epithelial cytoplasm with Alexafluor 647, p27 with Alexafluor 488, and nuclei with 4c6-diamidino-2-phenylindole·2HCl. Slides were scanned on an iCys laser scanning cytometer (CompuCyte Corp, Cambridge, MA). Nuclear crowding required a stereological approach--random arrays of circles (phantoms) were layered on images and the content of each phantom was analyzed in scatter plots. Both nuclear and cytoplasmic p27 were significantly lower in cases versus controls (P = .014 and P = .004, respectively). Regression models controlling for matching variables plus prostate-specific antigen showed strong linear trends for increased risk of recurrence with lower p27 in both nucleus and cytoplasm (highest versus lowest quartile; odds ratio, 0.35; P = .006). Manual scoring identified an inverse association between p27 expression and tumor grade but no independent association with recurrence. In conclusion, we developed an automated method for subcellular scoring of p27 without the need to segment individual cells. Our method identified a strong relationship, independent of tumor grade, stage, and prostate-specific antigen, between p27 expression--regardless of subcellular location--and prostate cancer recurrence. This relationship was not observed with manual scoring.

Indexed as

AdenocarcinomaBiomarkers, TumorCell NucleusCyclin-Dependent Kinase Inhibitor p27CytoplasmHumansImage Processing, Computer-AssistedMaleMicroscopy, FluorescenceMiddle AgedNeoplasm Recurrence, LocalPrognosisProstatic NeoplasmsReproducibility of ResultsTissue Array AnalysisBiomarkers, TumorCyclin-Dependent Kinase Inhibitor p27

Identifiers

PMID21292307
PMCPMC3095701
OpenAlexW1995157477

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.